Acorah Software Products - Accounts Production 19.1.200 false true true 31 December 2024 1 January 2024 false 1 January 2025 31 December 2025 31 December 2025 13198315 Professor G M Jackson Mr K Moss Dr B Morera Maiquez Mr P M Cable Mr D J O'Reilly Mr I Rhodes false iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 13198315 2024-12-31 13198315 2025-12-31 13198315 2025-01-01 2025-12-31 13198315 frs-core:CurrentFinancialInstruments 2025-12-31 13198315 frs-core:ComputerEquipment 2025-12-31 13198315 frs-core:ComputerEquipment 2025-01-01 2025-12-31 13198315 frs-core:ComputerEquipment 2024-12-31 13198315 frs-core:PlantMachinery 2025-12-31 13198315 frs-core:PlantMachinery 2025-01-01 2025-12-31 13198315 frs-core:PlantMachinery 2024-12-31 13198315 frs-core:SharePremium 2025-01-01 2025-12-31 13198315 frs-core:SharePremium 2025-12-31 13198315 frs-core:ShareCapital 2025-01-01 2025-12-31 13198315 frs-core:ShareCapital 2025-12-31 13198315 frs-core:RetainedEarningsAccumulatedLosses 2025-01-01 2025-12-31 13198315 frs-core:RetainedEarningsAccumulatedLosses 2025-12-31 13198315 frs-bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 13198315 frs-bus:FilletedAccounts 2025-01-01 2025-12-31 13198315 frs-bus:SmallEntities 2025-01-01 2025-12-31 13198315 frs-bus:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 13198315 frs-bus:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 13198315 frs-bus:OrdinaryShareClass1 2025-01-01 2025-12-31 13198315 frs-bus:OrdinaryShareClass1 2025-12-31 13198315 frs-bus:OrdinaryShareClass2 2025-01-01 2025-12-31 13198315 frs-bus:OrdinaryShareClass2 2025-12-31 13198315 frs-bus:OrdinaryShareClass3 2025-01-01 2025-12-31 13198315 frs-bus:OrdinaryShareClass3 2025-12-31 13198315 frs-bus:OrdinaryShareClass4 2025-01-01 2025-12-31 13198315 frs-bus:OrdinaryShareClass4 2025-12-31 13198315 frs-bus:OrdinaryShareClass5 2025-01-01 2025-12-31 13198315 frs-bus:OrdinaryShareClass5 2025-12-31 13198315 1 2025-01-01 2025-12-31 13198315 frs-bus:Director1 2025-01-01 2025-12-31 13198315 frs-bus:Director2 2025-01-01 2025-12-31 13198315 frs-bus:Director3 2025-01-01 2025-12-31 13198315 frs-bus:Director4 2025-01-01 2025-12-31 13198315 frs-bus:Director5 2025-01-01 2025-12-31 13198315 frs-bus:Director6 2025-01-01 2025-12-31 13198315 frs-countries:EnglandWales 2025-01-01 2025-12-31 13198315 2023-12-31 13198315 2024-12-31 13198315 2024-01-01 2024-12-31 13198315 frs-core:CurrentFinancialInstruments 2024-12-31 13198315 frs-core:SharePremium 2023-12-31 13198315 frs-core:SharePremium 2024-12-31 13198315 frs-core:ShareCapital 2023-12-31 13198315 frs-core:ShareCapital 2024-12-31 13198315 frs-core:RetainedEarningsAccumulatedLosses 2024-01-01 2024-12-31 13198315 frs-core:RetainedEarningsAccumulatedLosses frs-core:PreviouslyStatedAmount 2023-12-31 13198315 frs-core:RetainedEarningsAccumulatedLosses 2024-12-31 13198315 frs-bus:OrdinaryShareClass1 2024-01-01 2024-12-31 13198315 frs-bus:OrdinaryShareClass2 2024-01-01 2024-12-31 13198315 frs-bus:OrdinaryShareClass3 2024-01-01 2024-12-31 13198315 frs-bus:OrdinaryShareClass4 2024-01-01 2024-12-31 13198315 frs-bus:OrdinaryShareClass5 2024-01-01 2024-12-31
Registered number: 13198315
Neurotherapeutics Ltd
Financial Statements
For The Year Ended 31 December 2025
AVL Business Advisory Limited
Contents
Page
Balance Sheet 1—2
Statement of Changes in Equity 3
Notes to the Financial Statements 4—7
Page 1
Balance Sheet
Registered number: 13198315
2025 2024
Notes £ £ £ £
FIXED ASSETS
Tangible Assets 4 109,023 61,474
109,023 61,474
CURRENT ASSETS
Stocks 5 14,030 -
Debtors 6 251,285 246,312
Cash at bank and in hand 947,079 1,995,832
1,212,394 2,242,144
Creditors: Amounts Falling Due Within One Year 7 (246,210 ) (104,259 )
NET CURRENT ASSETS (LIABILITIES) 966,184 2,137,885
TOTAL ASSETS LESS CURRENT LIABILITIES 1,075,207 2,199,359
NET ASSETS 1,075,207 2,199,359
CAPITAL AND RESERVES
Called up share capital 8 2,106 2,043
Share premium account 4,693,630 4,693,624
Profit and Loss Account (3,620,529 ) (2,496,308 )
SHAREHOLDERS' FUNDS 1,075,207 2,199,359
Page 1
Page 2
For the year ending 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Mr P M Cable
Director
27 April 2026
The notes on pages 4 to 7 form part of these financial statements.
Page 2
Page 3
Statement of Changes in Equity
Share Capital Share Premium Profit and Loss Account Total
£ £ £ £
As at 1 January 2024 1,090 1,642,324 (1,434,584 ) 208,830
Loss for the year and total comprehensive income - - (1,061,724 ) (1,061,724)
Arising on shares issued during the period 953 3,051,300 - 3,052,253
As at 31 December 2024 and 1 January 2025 2,043 4,693,624 (2,496,308 ) 2,199,359
Loss for the year and total comprehensive income - - (1,124,221 ) (1,124,221)
Arising on shares issued during the period 63 6 - 69
Purchase of own shares (2 ) - - (2)
As at 31 December 2025 2,106 4,693,630 (3,620,529 ) 1,075,207
Page 3
Page 4
Notes to the Financial Statements
1. General Information
Neurotherapeutics Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 13198315 . The registered office is The Ingenuity Centre, UNIP, Triumph Road, Nottingham, Nottinghamshire, NG7 2TU.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Going Concern Disclosure
The directors have not identified any material uncertainties related to events or conditions that may cast significant doubt about the company's ability to continue as a going concern.
The directors are sufficiently confident that the company can raise capital within the next 12 months as required.
2.3. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:
Plant & Machinery 5 years straight line
Computer Equipment 3 years straight line
2.4. Stocks and Work in Progress
Stocks and work in progress are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. Work-in-progress is reflected in the accounts on a contract by contract basis by recording turnover and related costs as contract activity progresses.
2.5. Financial Instruments
Financial Instruments
i. Financial assets
Basic financial assets, including trade and other receivables, cash and bank balances and investments in commercial paper, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.
Such assets are subsequently carried at amortised cost using the effective interest method. At the end of each reporting period financial assets measured at amortised cost are assessed for objective evidence of impairment. If an asset is impaired the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.
If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.
Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.
ii. Financial liabilities
Basic financial liabilities, including trade and other payables and bank loans, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
...CONTINUED
Page 4
Page 5
2.5. Financial Instruments - continued
Fees paid on the establishment of loan facilities are recognised as transaction costs of the loan to the extent that it is probable that some or all of the facility will be drawn down. In this case, the fee is deferred until the draw-down occurs. To the extent there is no evidence that it is probable that some or all of the facility will be drawn down, the fee is capitalised as a pre-payment for liquidity services and amortised over the period of the facility to which it relates.
Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade payables are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
Share Capital
Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.
Distributions to equity holders
Dividends and other distributions to company’s shareholders are recognised as a liability in the financial statements in the period in which the dividends and other distributions are approved by the company’s shareholders. These amounts are recognised in the statement of changes in equity.
2.6. Foreign Currencies
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
2.7. Taxation
Income tax expense represents the sum of the tax currently payable and deferred tax.
The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.
Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.
Current and deferred tax are recognised in profit or loss for the year, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case current and deferred tax are recognised in other comprehensive income or directly in equity respectively.
2.8. Pensions
The company operates a defined pension contribution scheme. Contributions are charged to the profit and loss account as they become payable in accordance with the rules of the scheme.
Page 5
Page 6
2.9. Government Grant
Government grants are recognised in the profit and loss account in an appropriate manner that matches them with the expenditure towards which they are intended to contribute.
Grants for immediate financial support or to cover costs already incurred are recognised immediately in the profit and loss account. Grants towards general activities of the entity over a specific period are recognised in the profit and loss account over that period.
Grants towards fixed assets are recognised over the expected useful lives of the related assets and are treated as deferred income and released to the profit and loss account over the useful life of the asset concerned.
All grants in the profit and loss account are recognised when all conditions for receipt have been complied with.
3. Average Number of Employees
Average number of employees, including directors, during the year was: 11 (2024: 9)
11 9
4. Tangible Assets
Plant & Machinery Computer Equipment Total
£ £ £
Cost
As at 1 January 2025 60,281 8,525 68,806
Additions 64,240 416 64,656
As at 31 December 2025 124,521 8,941 133,462
Depreciation
As at 1 January 2025 5,639 1,693 7,332
Provided during the period 14,156 2,951 17,107
As at 31 December 2025 19,795 4,644 24,439
Net Book Value
As at 31 December 2025 104,726 4,297 109,023
As at 1 January 2025 54,642 6,832 61,474
5. Stocks
2025 2024
£ £
Stock 14,030 -
6. Debtors
2025 2024
£ £
Due within one year
Prepayments and accrued income 3,827 4,149
Other debtors 2,812 23,499
Corporation tax recoverable assets 244,646 218,664
251,285 246,312
Page 6
Page 7
7. Creditors: Amounts Falling Due Within One Year
2025 2024
£ £
Trade creditors 44,767 56,021
Other taxes and social security 26,695 21,394
VAT 141 -
Other creditors 614 114
Accruals and deferred income 173,993 26,730
246,210 104,259
8. Share Capital
2025 2024
Allotted, called up and fully paid £ £
108,753 Ordinary £0.01 Shares of £ 0.01000 each 1,087 1,089
52,554 University Ordinary shares of £ 0.00001 each 1 1
77,686 Seed1 £0.01 shares of £ 0.01000 each 777 777
23,864 B Ordinary shares of £ 0.01000 each 239 176
194 Deferred Shares of £ 0.01000 each 2 -
2,106 2,043
9. Controlling Party Not Known
The company does not have an ultimate controlling party.
Page 7